Login to Your Account



FDA Cites GI Side Effects

Idenix's HCV Drug On Hold; 'Not Optimistic,' CEO Says

By Randall Osborne


Monday, July 16, 2007
Idenix Pharmaceuticals Inc.'s FDA-ordered clinical hold on the nucleoside inhibitor valopicitabine for hepatitis C virus comes just a month after encouraging Phase II data, and probably means death for the drug also known as NM283, thanks to gastrointestinal side effects that the agency found serious enough to stop development. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription